NBASP downregulates FABP5 in NB, inactivating MAPK and suppressing carcinogenesis. FABP5 enhances tumorigenic pathways (e.g., MYCN, E2F1, SREBF1/2) and lipid metabolism in NB and OS. Imbalanced CRABP-II↓/FABP5↑ leads to RA resistance in MB. The gene discussed is MYCN; the disease is neuroblastoma.